These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5087 related articles for article (PubMed ID: 4343973)

  • 1. Tumorigenicity, immunogenicity, and virus production in mouse melanoma cells treated with 5-bromodeoxyuridine.
    Silagi S; Beju D; Wrathall J; Deharven E
    Proc Natl Acad Sci U S A; 1972 Nov; 69(11):3443-7. PubMed ID: 4343973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of antigenicity of melanoma cells grown in 5-bromodeoxyuridine to reduced tumorigenicity.
    Silagi S; Newcomb EW; Weksler ME
    Cancer Res; 1974 Jan; 34(1):100-4. PubMed ID: 4358536
    [No Abstract]   [Full Text] [Related]  

  • 3. Murine leukemia virus: high-frequency activation in vitro by 5-iododeoxyuridine and 5-bromodeoxyuridine.
    Lowy DR; Rowe WP; Teich N; Hartley JW
    Science; 1971 Oct; 174(4005):155-6. PubMed ID: 4330367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of melanoma cell tyrosinase activity and tumorigenicity after incorporation of bromouracil for one or two cell divisions.
    Wrathall JR; Newcomb EW; Balint R; Zeitz L; Silagi S
    J Cell Physiol; 1975 Dec; 86 Suppl 2(3 Pt 2):581-92. PubMed ID: 811676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of pigmentation in mouse melanoma cells by 5-bromodeoxyuridine: effects on tyrosinase activity and melanosome formation.
    Wrathall JR; Oliver C; Silagi S; Essner E
    J Cell Biol; 1973 May; 57(2):406-23. PubMed ID: 4633171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlated suppression by 5-bromodeoxyuridine of tumorigenicity and plasminogen activator in mouse melanoma cells.
    Christman JK; Silagi S; Newcomb EW; Silverstein SC; Acs G
    Proc Natl Acad Sci U S A; 1975 Jan; 72(1):47-50. PubMed ID: 123336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
    Stackpole CW; Demsey A
    Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology and host response associated with reduced tumorigenicity of 5-bromodeoxyuridine--treated murine melanoma cells.
    Gyi KK; Wrathall JR
    Am J Pathol; 1983 Feb; 110(2):135-47. PubMed ID: 6824061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased virus budding from Friend erythroleukemic cells treated with dimethyl sulfoxide, dimethyl formamide, and/or bromodeoxyuridine in vitro.
    Sato T; de Harven E; Friend C
    Bibl Haematol; 1975; (40):143-51. PubMed ID: 1057942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased susceptibility of murine teratocarcinoma cells to Simian virus 40 and polyoma virus following treatment with 5-bromodeoxyuridine.
    Speers WC; Lehman JM
    J Cell Physiol; 1976 Jul; 88(3):297-305. PubMed ID: 178674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutants of nonproducer cell lines transformed by murine sarcoma viruses. I. Induction, isolation, particle production, and tumorigenicity.
    Hatanaka M; Klein R; Toni R; Walker J; Gilden R
    J Exp Med; 1973 Aug; 138(2):356-63. PubMed ID: 4352583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between rejection of several syngeneic tumors and retrovirus production by 5-bromodeoxyuridine-grown melanoma cells: lack of protection in natural killer-deficient beige mice.
    Silagi S; Calvelli TA
    Cancer Res; 1982 Jul; 42(7):2562-6. PubMed ID: 7083149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible suppression of malignancy and differentiation of melanoma cells.
    Silagi S
    Am J Pathol; 1977 Dec; 89(3):671-84. PubMed ID: 596422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 5-bromodeoxyuridine on tumorigenicity, immunogenicity, virus production, plasminogen activator, and melanogenesis of mouse melanoma cells.
    Silagi S
    Int Rev Cytol; 1976; 45():65-111. PubMed ID: 821894
    [No Abstract]   [Full Text] [Related]  

  • 15. Suppression of malignancy and differentiation in melanotic melanoma cells.
    Silagi S; Bruce SA
    Proc Natl Acad Sci U S A; 1970 May; 66(1):72-8. PubMed ID: 4921328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous production of mouse endogenous virus and Rous sarcoma virus by Schmidt-Ruppin virus infected mouse cells.
    Kotler M; Lerer I; Moyal ZB; Spira G
    J Gen Virol; 1978 Jul; 40(1):141-50. PubMed ID: 211179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the mechanism of induction of infectious murine leukemia virus from AKR mouse embryo cell lines by 5-iododeoxyuridine and 5-bromodeoxyuridine.
    Teich N; Lowy DR; Hartley JW; Rowe WP
    Virology; 1973 Jan; 51(1):163-73. PubMed ID: 4346294
    [No Abstract]   [Full Text] [Related]  

  • 18. An improved murine leukemia virus immunofluorescence assay.
    Declève A; Niwa O; Hilgers J; Kaplan HS
    Virology; 1974 Feb; 57(2):491-502. PubMed ID: 4361458
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of Friend erythroleukemic cell differentiation by bromodeoxyuridine: correlation with the amount of bromodeoxyuridine in DNA.
    Ashman CR; Davidson RL
    J Cell Physiol; 1980 Jan; 102(1):45-50. PubMed ID: 6445371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Synthesis of group-specific antigen of murine oncornaviruses in chronically infected cells].
    Al'tshteĭn AD; Argirova RM; Gerasina SF; Karelin VP; Zhdanov VM
    Vopr Virusol; 1975; (1):94-6. PubMed ID: 164738
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 255.